Oscotec Valuation

Q: What is the Fair Price of A039200 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A039200 (₩33900) is trading below our estimate of [[fair value]] (₩65583.14)

Is A039200 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A039200 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A039200 (₩33900) is trading below our estimate of fair value (₩65583.14)

Significantly Below Fair Value: A039200 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A039200?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A039200. This is calculated by dividing A039200's market cap by their current preferred multiple.
What is A039200's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩1.29t

A039200 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	266.1x
Enterprise Value/EBITDA	-38.8x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A039200's PB Ratio compare to its peers?

The above table shows the PB ratio for A039200 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.3x
A140410 Mezzion PharmaLtd	16.7x	n/a	₩919.1b
A185750 Chong Kun Dang Pharmaceutical	1.6x	-18.6%	₩1.4t
A069620 Daewoong Pharmaceutical	1.9x	17.8%	₩1.5t
A003090 Daewoong	1x	n/a	₩963.0b
A039200 Oscotec	14.9x	122.0%	₩1.3t

Price-To-Book vs Peers: A039200 is expensive based on its Price-To-Book Ratio (14.9x) compared to the peer average (5.3x).

Price to Earnings Ratio vs Industry

How does A039200's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	39.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	39.1%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: A039200 is expensive based on its Price-To-Book Ratio (14.9x) compared to the KR Pharmaceuticals industry average (1.2x).

Price to Book Ratio vs Fair Ratio

What is A039200's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A039200 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	14.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A039200's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A039200 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	₩33,900.00	₩56,000.00 +65.2%	5.4%	₩59,000.00	₩53,000.00	n/a	2
Sep ’25	₩41,950.00	₩56,000.00 +33.5%	5.4%	₩59,000.00	₩53,000.00	n/a	2
Aug ’25	₩41,450.00	₩56,000.00 +35.1%	5.4%	₩59,000.00	₩53,000.00	n/a	2
Jul ’25	₩41,400.00	₩46,500.00 +12.3%	14.0%	₩53,000.00	₩40,000.00	n/a	2
Jun ’25	₩30,600.00	₩46,500.00 +52.0%	14.0%	₩53,000.00	₩40,000.00	n/a	2
May ’25	₩30,650.00	₩46,500.00 +51.7%	14.0%	₩53,000.00	₩40,000.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.